Literature DB >> 8668854

Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects.

S Jenison1, B Hjelle, S Simpson, G Hallin, R Feddersen, F Koster.   

Abstract

Hantavirus pulmonary syndrome is an acute pneumonitis with a high mortality rate that is caused by a newly recognized hantavirus. Four Corners virus (also known as Muerto Canyon virus and Sin Nombre virus) is enzootic among deer mice (Peromyscus maniculatus). Incidental transmission to humans can result in a disease characterized by rapidly progressive respiratory insufficiency, diffuse noncardiogenic pulmonary edema, vascular volume contraction with hemoconcentration, lactic acidosis, depressed cardiac output, and cardiac dysrhythmias preterminally. The onset of pulmonary edema is preceded by a prodrome of fever and severe myalgias. Characteristic laboratory abnormalities include thrombocytopenia, leukocytosis with prevalent immature myeloid cells, and the presence of immunoblastic lymphocytes in the peripheral blood. Agent-specific diagnosis is based on the detection of Four Corners virus-specific antibodies in serum by Western blot assays and the detection of Four Corners virus RNA in peripheral blood mononuclear cells by the reverse transcriptase-polymerase chain reaction. Effective treatment depends on the rapid institution of intensive care support.

Entities:  

Mesh:

Year:  1995        PMID: 8668854

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  11 in total

1.  Environmental Variables Associated with Hantavirus Reservoirs and Other Small Rodent Species in Two National Parks in the Paraná Delta, Argentina: Implications for Disease Prevention.

Authors:  María Victoria Vadell; Isabel Elisa Gómez Villafañe
Journal:  Ecohealth       Date:  2016-05-11       Impact factor: 3.184

2.  Antagonism of type I interferon responses by new world hantaviruses.

Authors:  Jessica R Levine; Joseph Prescott; Kyle S Brown; Sonja M Best; Hideki Ebihara; Heinz Feldmann
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

3.  Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis.

Authors:  Marcos L Moreli; Ariany C Marques-Silva; Vagner A Pimentel; Vivaldo G da Costa
Journal:  Virusdisease       Date:  2014-06-04

4.  Hantaviruses in the americas and their role as emerging pathogens.

Authors:  Brian Hjelle; Fernando Torres-Pérez
Journal:  Viruses       Date:  2010-11-25       Impact factor: 5.048

5.  Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.

Authors:  Virginie Bondu; Ron Schrader; Mary Ann Gawinowicz; Paul McGuire; Daniel A Lawrence; Brian Hjelle; Tione Buranda
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

6.  Hantavirus Infection Suppresses Thrombospondin-1 Expression in Cultured Endothelial Cells in a Strain-Specific Manner.

Authors:  Svetlana F Khaiboullina; Sergey P Morzunov; Stephen C St Jeor; Albert A Rizvanov; Vincent C Lombardi
Journal:  Front Microbiol       Date:  2016-07-19       Impact factor: 5.640

7.  Atypical case of hantavirus infection in Sri Lanka mimicking leptospirosis: a case report.

Authors:  Chamara Dalugama; Madushi Nanayakkara; Nimanthi Rathnayaka; Arjuna Medagama
Journal:  J Med Case Rep       Date:  2020-06-18

8.  Person-to-person transmission of Andes virus.

Authors:  Valeria P Martinez; Carla Bellomo; Jorge San Juan; Diego Pinna; Raul Forlenza; Malco Elder; Paula J Padula
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

9.  Upregulation of P2Y2R, Active uPA, and PAI-1 Are Essential Components of Hantavirus Cardiopulmonary Syndrome.

Authors:  Virginie Bondu; Casey Bitting; Valerie L Poland; Joshua A Hanson; Michelle S Harkins; Sarah Lathrop; Kurt B Nolte; Daniel A Lawrence; Tione Buranda
Journal:  Front Cell Infect Microbiol       Date:  2018-05-23       Impact factor: 5.293

Review 10.  Hantavirus Cardiopulmonary Syndrome in Canada.

Authors:  Bryce M Warner; Sebastian Dowhanik; Jonathan Audet; Allen Grolla; Daryl Dick; James E Strong; Darwyn Kobasa; L Robbin Lindsay; Gary Kobinger; Heinz Feldmann; Harvey Artsob; Michael A Drebot; David Safronetz
Journal:  Emerg Infect Dis       Date:  2020-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.